Where Scale-Up Can Slow Down
The scale-up story in biologics often centers on cell culture: bigger tanks, more cells, more product. It's the part of the process most visible from outside the building, and it tends to drive much of the public conversation around capacity.
But ask anyone who has lived through a slipped timeline what actually held the program up, and the answer can often be downstream. Purification steps don't always behave the same way at a new scale, in a new building, or with a new team. The result can be months of unexpected work in the part of the process people had assumed was settled.
Where downstream can slow things down
A handful of failure modes tend to come up repeatedly, often in some combination.
1. Setting up the same step at a new scale
Some traditional purification setups can be difficult to reproduce exactly when they're built bigger. Small differences in setup, such as column packing, can show up as performance differences that look like process failures. Column packing is a good example: how well a column is packed varies with operator technique and equipment, and each new column usually has to be qualified before the step can be trusted. Each rebuild can be a calendar event, a documentation exercise, and a risk in its own right.
2. Variability in materials
The materials used in many traditional purification steps can vary from batch to batch. A new batch may shift performance just enough to disrupt comparability between runs, even when the same procedure is followed step by step. Qualifying each new batch can take time and resources, and the qualification work tends to fall on the critical path.
3. Performance differences across scales
A step that works well at bench scale doesn't always behave identically at commercial scale. The geometry can change, residence times can shift, and the differences may require additional comparability studies to sort out. Those studies often take longer than programs budget for.
4. Differences between sites
Equipment, control systems, and standard procedures can vary between sites in ways that are hard to fully predict on paper. The more bespoke a purification step is, the harder it can be to move. This can be especially painful for contract manufacturers and multi-site operations, where transfers are part of the business model rather than a one-time event.
What this can cost
The costs of a slow downstream transfer rarely show up neatly in any one place.
· Months lost on the critical path: sometimes the difference between hitting and missing a clinical milestone.
· Material spent on troubleshooting and engineering runs that was originally meant for clinical or commercial supply.
· Higher regulatory scrutiny, because more deviations during transfer can mean more questions on file.
· For contract manufacturers, every slipped transfer can crowd out the next program in the queue.
Each of these can usually be managed in isolation. Stacked together, they're often the difference between a program that ships on time and one that doesn't.
What can make scale-up easier
Not every purification technology carries the same scale-up risk. Some choices made early in development can quietly carry programs through transitions later.
1. Choices that reduce variability
Pre-validated, standardized formats such as pre-packed columns can remove some of the most common variables, simply because there's less to assemble and qualify each time. Approaches that scale by area rather than by traditional column dimensions tend to behave more predictably from bench through commercial scale, because the underlying behavior doesn't change as much as the equipment around it does.
2. Designing for the long run early
The technology decisions made early in development can quietly shape everything that comes after. Design choices supporting lower buffer requirements, simpler equipment, and broadly available formats can each reduce the likelihood for things to go wrong later.
3. Vendor and regulatory familiarity
Technologies that regulators are already comfortable with can help shorten review timelines. Vendors that support the full scale range, from bench through commercial, can matter more in the second year of a program than the first, when the questions start focusing on how the process will behave at the next scale up.
A different question to ask in development
The usual development question is which technology gives the best yield and purity right now. A useful complement: which technology may still look the same three years from now, at a different scale, in a different building, with a different team? The second question can be the one that helps turn a strong process into a commercial product.
Key takeaways
· Scale-up slips often happen downstream rather than upstream, and the reasons can be more predictable than they look.
· The most common slowdowns tend to come from reproducing steps at new scales, material variability, performance differences across scales, and site-to-site differences.
· Purification approaches that are standardized, that scale predictably, and that use less buffer can carry less scale-up risk.
· One of the higher-leverage decisions a downstream team makes can be choosing for the long run, not just for the next study.
Ready to learn more?
See how Purexa™ membrane chromatography supports predictable scale-up and tech transfer.
